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Abstract: Background: Recently, the European Working Group on Sarcopenia in Older People 
(EWGSOP2) has updated the sarcopenia definition based on objective evaluation of muscle strength, 
mass and physical performance. The aim of this study was to analyse the relationship between 
sarcopenia and clinical aspects such as functionality, comorbidity, polypharmacy, hospitalisations 
and falls in order to support sarcopenia screening in institutionalised older adults, as well as to 
estimate the prevalence of sarcopenia in this population using the EWGSOP2 new algorithm. 
Methods: A multicentre cross-sectional study was conducted on institutionalised older adults (n = 
132, 77.7% female, mean age 82 years). Application of the EWGSOP2 algorithm consisted of the 
SARC-F questionnaire, handgrip strength (HG), appendicular skeletal muscle mass index (ASMI) 
and Short Physical Performance Battery (SPPB). Clinical study variables were: Barthel Index (BI), 
Abbreviated Charlson’s Comorbidity Index (ACCI), number of medications, hospital stays and falls. 
Results: Age, BI and ACCI were shown to be predictors of the EWGSOP2 sarcopenia definition 
(Nagelkerke’s R-square = 0.34), highlighting the ACCI. Sarcopenia was more prevalent in older 
adults aged over 85 (p = 0.005), but no differences were found according to gender (p = 0.512). 
Conclusion: BI and the ACCI can be considered predictors that guide healthcare professionals in 
early sarcopenia identification and therapeutic approach. 
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Int. J. Environ. Res. Public Health 2020, 17, 4483 2 of 15 
 
1. Introduction 
Population aging is a worldwide phenomenon which has been expressive and accelerated over 
the years [1]. Therefore, geriatric syndromes, such as sarcopenia with a higher prevalence among 
institutionalised older adults (14–33%) than those living in community (1–29%) [2,3], has a 
considerable clinical and research interest [4]. 
The most widely used definition of sarcopenia is the one of the European Working Group on 
Sarcopenia in Older People (EWGSOP) [5,6], which was updated in 2018 (EWGSOP2) and focuses on 
low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and 
quality to confirm the diagnosis and identifies poor physical performance as indicative of severity 
[7]. Sarcopenia has also been associated with increased risk of falls, impaired ability to perform 
activities of daily living and, consequently, it can cause functional dependency and disability in older 
adults [5,8]. However, most of this previous research has mainly focused on older adults living in the 
community rather than on institutionalised people [3]. Taking into account that strong evidence 
predictors of institutionalisation in older adults are functional impairment, cognitive impairment, 
higher age, low self-related health status and a high number of prescriptions [9], it could be suggested 
that older adults with sarcopenia living in institutions could even have a higher prevalence of some 
of these adverse outcomes related to sarcopenia, such as functional capacity impairment, 
dependence, falls, physical disability, negative impact on quality of life, hospitalisation and even 
death [10–13]. 
Assessment of sarcopenia needs measurement instruments for objective evaluation of muscle 
strength, mass and function, which also requires substantial time. Hence, screening of sarcopenia 
with user friendly, simple tools is required [14]. Clinical aspects and measurements such as 
functionality, comorbidities, number of drugs, number of hospitalisations and number of falls are 
widely used tools in residential facilities for assessing health and do not require specific and 
expensive medical equipment. However, the few studies that have focused on institutionalised 
people have shown isolated results of one or other characteristic, and not on a comprehensive 
perspective which is what defines a person’s health. Thus, functional capacity has been assessed 
mainly through the Barthel Index [15–17] and it has shown that participants diagnosed with 
sarcopenia tend to have worse functional status [15]. Others studies have identified the comorbidities 
of institutionalised people, quantifying the number of diseases [15–18] or using the Charlson’s 
Comorbidity Index [19]. Generally, those that relate it to sarcopenia show no differences in 
prevalence of diseases between the sarcopenic or non-sarcopenic groups [15,19]. Some studies have 
used variables such as number of drugs or number of hospitalisations in order to describe the 
participants [15,18] but no relationship has been established with sarcopenia. A number of falls have 
been quantified in institutionalised older adults with sarcopenia with no significant relationship [15]. 
For the moment, the variables that have been mainly associated with sarcopenia in institutionalised 
older people are the anthropometric ones (age, gender and body mass index) [15]. 
Therefore, some bivariate relationships have been studied between variables widely used in the 
clinical context and with sarcopenic institutionalised older people, but research in this area is still 
sparse. Moreover, the different combinations of functional and clinical variables in relation to 
sarcopenia in a multivariate framework remain to be elucidated. Thus, to the best of our knowledge, 
there is no study evaluating sarcopenia according to EWGSOP2 criteria and relating it with 
functionality, comorbidities, number of drugs, number of hospitalisations and number of falls in 
institutionalised older people in order to help clinicians in the screening and detection of sarcopenia 
in this population. 
It was hypothesised that institutionalised older people suffering from sarcopenia as defined by 
the EWGSOP2 criteria and cut-off points would have a lower functional capacity, higher number of 
hospitalisations, higher number of drugs used, higher number of falls and higher index of 
comorbidities when analysed individually. Moreover, the combination of these factors may correlate 
higher to sarcopenia and help in the screening process. 
The main aim of this study was to analyse the relationship between sarcopenia and functional 
ability, hospitalisation, number of falls, polypharmacy and comorbidity in order to support and 
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facilitate sarcopenia screening in institutionalised older adults. A secondary aim was to identify 
which of our clinical and functional variables are the most relevant as supporting tools for screening 
sarcopenia and to estimate the prevalence of sarcopenia in institutionalised older adults using the 
new algorithm of the EWGSOP2. 
2. Materials and Methods 
2.1. Study Design 
A multicentre cross-sectional study was carried out between January and November 2019 in 
institutionalised older adults living in the province of Valencia (Spain). 
This study was approved by the Ethics Committee for Human Research of University of 
Valencia (H1542733812827) and was conducted in accordance with the Declaration of Helsinki. This 
research was registered in the ClinicalTrials.gov (ID: NCT03832608). All participants were briefed 
beforehand and all signed a written consent form before participating in the study. 
2.2. Participants 
The sample included adults institutionalised in residential facilities, aged 65 or older. The 
exclusion criteria were: (1) patients with edema that could alter the bioimpedance analysis (BIA) 
results; (2) Mini-Mental State Examination (MMSE) < 18 points [20]; (3) acute disease, hospital 
admission or unstable chronic disease in the last month. 
2.3. Sarcopenia Definition 
The EWGSOP2 has proposed an algorithm for case-finding, diagnosis and severity 
determination [7] which includes the SARC-F questionnaire, the measurement of muscle strength, 
muscle quantity or quality, and the identification of physical performance. 
Following this algorithm, in this study the measured parameters to identify sarcopenia cases 
and its level of severity were: 
The SARC-F is a 5-item questionnaire (strength, assistance walking, rise from a chair, climb 
stairs, and falls) based on cardinal features or consequences of sarcopenia, that allows to identify 
cases when the score is  4 points out of 12 for the total score [21]. 
Muscle strength (kg), was measured by the handgrip strength technique using a Jamar Plus+ 
digital hand dynamometer (Patterson Medical, Sammons Preston, Bolingbrook, Ill, USA) [22]. Grip 
strength cut-off points for low strength were <27 kg and <16 kg for men and women, respectively 
[23]. 
Muscle quantity or Appendicular Skeletal Muscle Mass (ASM) was measured with BIA using the 
Bodystat® 1500MDD (Bodystat Ltd., Douglas, UK). The device was calibrated daily using the 
standard control circuit supplied by the manufacturer. Before doing the test, participants were asked 
to follow these instructions [15]: (1) no previous physical exercise; (2) 2–3 h of fasting; (3) no alcohol 
or large amount of water intake; (4) urinating 30 min before; (5) every metal piece (such as a watch, 
jewellery) was taken off. Moreover, the test was not conducted in participants wearing a pacemaker 
and/or with edema [24]. The edema was assessed and diagnosed by the physician and recorded in 
clinical history. BIA test was done with the patient in supine position, on a non-conductive surface, 
ensuring that no parts of the body were touching. The patient stayed in this position for 5 min prior 
to measurement to ensure that fluid levels had stabilised in the body. Before placing the electrodes, 
the skin was cleaned with 70% alcohol. Using an ipsilateral tetrapolar method, the electrodes were 
placed behind the knuckle of the middle finger and on the wrist next to the ulna head (upper limb) 
and at the dorsal side of the second metatarsal head bone and on the ankle at the level of, and 
between, the medial and lateral malleoli (lower limb). The BIA was performed using an alternating 
sinusoidal electric current of 200 µA at a single operating frequency of 50 kHz. For estimating the 
ASM, the Sergi’s BIA equation was used: ASM (kg) = −3.964 + (0.227 × RI) + (0.095 × weight) + (1.384 × 
sex) + (0.064 × Xc) [25], where resistive index (RI) was resistance (ohms) normalised for height (cm), 
weight (kg), sex was 1 in men and 0 in women, and reactance (Xc, ohms). ASM cut-off points for low 
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mass were <20 kg and <15 kg for men and women, respectively. The ASM Index (ASMI) was defined 
as ASM/height squared. ASMI cut-off points for corrected low mass were <7.0 kg/m2 and <5.5 kg/m2 
for men and women, respectively [7]. 
Physical performance was assessed through gait speed (m/s) using a 4-m walking test [26], where 
<0.8 m/s was the cut-off point [5,27]. Participants had to walk at their usual walking speed and using 
their usual walking aid. Moreover, the physical performance was measured by the Short Physical 
Performance Battery (SPPB) [28], where 8 points was used as a cut-off point both in men and women. 
Finally, sarcopenia was classified in different severity levels according the EWGSOP2 [7]: 1) 
probable sarcopenia when SARC-F scored 4 points and there was low muscle strength (grip strength 
<27 kg and <16 kg in men and women, respectively); 2) confirmed sarcopenia when also low quantity 
muscle was detected (ASMI <7.0 kg/m2 and <6 kg/m2 in men and women, respectively); and 3) severe 
sarcopenia, when confirmed sarcopenia was summed up to low physical performance (SPPB  8 
point score). 
2.4. Measurements 
Added to the algorithm parameters established by the EWGSOP2, each participant underwent 
all of the following assessments on the same day. Different health professionals took these 
measurements. In order to avoid to inter-individual errors, intraclass correlation coefficients (ICCs) 
were calculated to know the interrater reliabilities. According to Koo and Li (2016) [29], values of 
ICCs between 0.75 and 0.9 indicate good reliability and values greater than 0.90 indicate excellent 
reliability. All ICCS in this study ranged from 0.802 to 0.985 which may be considered a very good 
reliability. 
The studied variables were: 
Anthropometric variables: (1) Age and gender; (2) body weight (kg), assessed using a Tanita BC 
601 model weighing device (TANITA Ltd., Tokyo, Japan); (3) barefoot standing height (cm), 
measured with a stadiometer SECA 213 (Seca Ltd., Hamburg, Germany); body mass index (BMI), 
calculated based on the parameters of weight (kg) divided by height squared (m2). 
Functional ability evaluation used the Barthel Index score [30]. This index was validated in older 
populations [31]. Values <20 points indicate total dependency for activities of daily living and scores 
between 21 and 60 indicate severe dependence [32]. 
Comorbidity severity was recorded using the Abbreviated Charlson’s Comorbidity Index [33]. It 
encompasses eight medical conditions (cerebral vascular disease, diabetes, chronic obstructive 
pulmonary disease, heart failure/ischemic heart disease, dementia, peripheral arterial disease, 
chronic kidney failure (dialysis) and cancer) with total scores ranging from 0–10, where 0 is no 
comorbidity and 10 is high comorbidity. On the other hand, this variable allows us to classify 
participants in relation to their comorbidity level (as the modified Abbreviated Charlson’s 
Comorbidity Index): absence of comorbidity is considered between 0 and 1 points, low comorbidity 
when the index is 2, and high comorbidity when it is 3 points. 
Number of medications taken daily on a regular basis. 
Number of hospital stays in the last year (recorded as the number of hospitalisations, either due to 
falls or any other clinical situation that required it). 
Falls were analysed as number of falls in the last year (including both falls that did not require 
hospitalisation and those that required hospitalisation/surgery), and also registered according to the 
SARC-F questionnaire falls item (named as “modified falls”): no falls, 1–2 falls and 3 falls [21]. 
2.5. Sample Size Calculation 
Given that the population size was larger than 100,000 and required accounting for the most 
variable situation (p = q = 0.5) with a confidence level of 95%, 375 subjects were needed. Of those, a 
stratification among institutionalised and community-dwelling adults were considered. For the 
purposes of this research, only institutionalised participants were considered. 
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2.6. Statistical Analyses 
For descriptive purposes, the mean and standard deviation for quantitative variables were 
calculated, whereas percentages were estimated for categorical variables. At the bivariate level of the 
relationship, several inferential tests were performed. Specifically, when means from a quantitative 
variable wanted to be compared across the levels of a factor, ANOVAs or t-tests were employed. 
Assumptions for the correct use of these parametric techniques were previously tested and 
opportune corrections were applied if necessary. Partial eta-squares were obtained as measures of 
effect size. When two categorical variables were related, independence chi-square tests were used 
with Cramer’s V and Kendall’s tau as measures of the effect size. Finally, a binary logistic regression 
was used to predict the likelihood of having sarcopenia at the multivariate level. Beta coefficients as 
well as the odds-ratio associated with each predictor were calculated. Additionally, two estimates of 
the overall predictive power of the logistic regression were calculated: Cox and Snell and 
Nagelkerke’s R-square. Given the available sample size a stepwise procedure was used to select the 
predictors in the logistic regression. All statistical tests employed were considered statistically 
significant at p < 0.05 and in all cases, appropriate measures of effect size were estimated. All statistical 
analyses were performed in SPSS 24. 
3. Results 
3.1. Sample Characteristics 
A total of 132 participants were included in this study. The age range for all the participants was 
65–97 years, and according to gender the range was 65–96 years old and 65–97 years old for men and 
women, respectively. The mean age was 82 ± 8.3 years old and 102 participants (77.7 %) were women 
(Table 1). 
Table 1. Characteristics of the participants according to gender: mean ± standard deviation and (95% 
confidence interval) or number of cases (percentages). 
Variables Total (n = 132) Men (n = 30) Women (n = 102) p-Value a 
Anthropometrics     
Age (years) 
82.03 ± 8.25 
(80.61–83.45) 
78.70 ± 8.73 
(75.44–81.96) 




66.66 ± 13.45 
(64.34–68.97) 
75.98 ± 12.60 
(71.28–80.69) 




154.02 ± 9.08 
(152.46–155.58) 
165.05 ± 8.00 
(162.07–168.04) 




 28.06 ± 4.89 
(27.22–28.90) 
27.92 ± 3.83 
(26.49–29.35) 
28.10 ± 5.17 
(27.09–29.11) 
0.831 
EWSGOP2 algorithm     
SARC-F (0–10 score) 
3.95 ± 2.59 
(3.50–4.39) 
3.63 ± 2.77 
(2.60–4.67) 
4.04 ± 2.54 
(3.54–4.54) 
0.453 
Grip strength (kg) 
18.77 ± 7.82 
(17.42–20.11) 
26.85 ± 9.89 
(23.16–30.55) 




15.10 ± 3.48 
(14.50–15.71) 
 19.63 ± 3.14 
(18.41–20.85) 




6.32 ± 0.98  
(6.15–6.49) 
7.20 ± 0.83 
(6.87–7.52) 
6.07 ± 0.87 
(5.90–6.24) 
<0.001 † 
Gait speed (m/s) 
0.56 ± 0.27 
(0.51–0.61) 
0.57 ± 0.29 
(0.46–0.68) 
0.56 ± 0.27 
(0.50–0.61) 
0.797 
SPPB (0–12 score) 
5.27 ± 2.99 
(4.75–5.78) 
6.17 ± 2.84 
(5.11–7.23) 
5.00 ± 2.99 
(4.41–5.59) 
0.06 
Study’s variables     
Barthel Index (0–100 score) 
77.95 ± 19.07 
(74.67–81.24) 
79.00 ± 22.87 
(70.46–87.54) 
77.65 ± 17.92 
(74.13–81.17) 
0.767 
Barthel Index classification     0.064 
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Independent (100) 
Mild dependence (91–99) 
Moderate dependence (61–90) 
Severe dependence (21–60) 
















Abbreviated Charlson’s  
Comorbidity Index (0–10)  
1.70 ± 1.33 
(1.47–1.93) 
2.27 ± 1.34 
(1.77–2.77) 
1.53 ± 1.29 
(1.28–1.78) 
<0.01 * 
Modified abbreviated Charlson’s   





















8.67 ± 4.37 
(7.92–9.43) 
9.00 ± 4.59 
(7.29–10.71) 
8.58 ± 4.32 
(7.73–9.43) 
0.644 
Hospitalisation stays (n) 
0.24 ± 0.59 
(0.14–0.34) 
0.23 ± 0.50 
(0.05–0.42) 




1.13 ± 2.08 
(0.77–1.49) 
0.93 ± 1.48 
(0.38–1.49) 
1.19 ± 2.22 
(0.75–1.62) 
0.56 

















Abbreviatures: BMI = Body Mass Index; SPPB = Short Physical Performance Battery; ASM = 
Appendicular Skeletal Muscle Mass; ASMI = ASM Index. a p-value unpaired Student’s t-test for 
quantitative variables and Chi-squared tests for qualitative variables; b Modified Charlson’s 
Comorbidity Index as a codification of total score in three comorbidity levels (Berkman et al., 1992) 
[33]; c Modified falls according to its registration through the SARC-F questionnaire by Malmstrom 
and colleagues (2016) [21]. * p < 0.05; † p < 0.01. 
Regarding the different cut-off points established by the EWGSOP2 algorithm, this study’s 
sample showed that men had a SARC-F mean under four points, whereas women’s mean was slightly 
over four. Grip strength values were just under cut-off points for men, and just over for women. 
Regarding ASM means in kg, both men and women scored below cut-off points, however, the ASM 
Index (kg/height2) means were just over cut-off points for both genders. In addition, muscle strength 
and quantity variables showed significant differences between gender (p < 0.001). Physical 
performance variables scored under cut-off points both for men and women, thus gait speed was 
below 0.8 m/s and SPPB was below eight points. In fact, both variables had means well below the cut-
off points (0.56 ± 0.27 m/s for gait speed and 5.27 ± 2.99 score for SPPB). Moreover, the results of the 
SPPB indicate that 61% of the sarcopenic participants presented with severe sarcopenia. 
In relation to the study variables, significant differences were found between genders for the 
two comorbidity-related variables measured. Women had significant lower mean than men in the 
Abbreviated Charlson’s Comorbidity Index (p < 0.01), and also the results of the modified 
Abbreviated Charlson’s Comorbidity Index for women indicated a better health status than men (p = 
0.027). Moreover, these findings highlighted that women have less comorbidity than men (“No 
comorbidity” 55.5% vs. 33.3%, respectively) in this sample. 
When all the steps of the EWSGOP2 algorithm were applied (Figure 1), the 132 institutionalised 
older adults were classified as follows: with no sarcopenia (n = 86, 65%), with probable sarcopenia 
which was not confirmed (n = 18, 14%), with confirmed sarcopenia (n = 0, 0%), and with confirmed- 
severe sarcopenia (n = 28, 21%). 
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Figure 1. Sarcopenia: EWSGOP2 algorithm for case-finding, diagnosis and quantification of severity 
in practice. 
3.2. Differences Based on EWSGOP2 Algorithm’s Application Regarding Study’s Variables 
Regarding the severity levels of sarcopenia according to the EWGSOP2, results showed 
significant differences between the Barthel Index and the Abbreviated Charlson’s Comorbidity Index. 
The statistical descriptions are provided in Table 2. Post-hoc comparisons in the Barthel Index found 
statistically significant differences between the “no sarcopenia” and “probable sarcopenia” 
participants (p = 0.003) and between the “no sarcopenia” and “severe sarcopenia” participants (p < 
0.001). Moreover, post-hoc comparisons in the Abbreviated Charlson’s Comorbidity Index found 
statistically significant differences between the “no sarcopenia” and “severe sarcopenia” participants 
(p = 0.004). 




Mean  SD F df df (error) p-Value 2 
Barthel Index (0–100 score) 
NS 83.26  16.90 
10.992 2 129 <0.001 † 0.146 PS 67.78  18.96 
SS 68.21  19.54 
Abbreviated Charlson’s 
Comorbidity Index (0–10) 
NS 1.42  1.30 
6.054 2 129 0.003 † 0.086 PS 2.06  1.26 
SS 2.32  1.25 
Medication (n) 
NS 8.43  4.57 
0.561 2 129 0.572 0.009 PS 9.61  4.07 
SS 8.82  3.94 
Hospitalisation stays (n) 
NS 0.17  0.47 
1.876 2 129 0.157 0.028 PS 0.44  1.04 
SS 0.32  0.55 
Falls (n) 
NS 1.07  2.39 
0.44 2 129 0.65 0.007 PS 1.56  1.72 
SS 1.04  1.0 
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Abbreviatures: SD = standard deviation; F = result of the F test; df = degrees of freedom; 2 Partial = 
partial eta-squared effect size; p = significance, † p < 0.01; NS = no sarcopenia; PS = probable sarcopenia; 
SS = severe sarcopenia. 
Results of the relationship between the functional and clinical variables with the sarcopenia 
severity levels are shown in Table 3. Although the effect size is low for all variables, results point out 
that non-sarcopenia participants were found among the independent and slightly moderate-
dependent older adults, while participants with some degree of sarcopenia mainly had moderate or 
severe dependence. On the other hand, the non-sarcopenic older adults had less comorbidity and 
number of falls. 




2 df p-Value Cramer’s V Kendall’s  
 NS PS SS      
Barthel Index classification  
Independent (100) 
Mild dependence (91–99) 
Moderate dependence (61–90) 
Severe dependence (21–60) 




































12.86 4 0.014 * 0.222 0.285 
















14.87 4 0.005 † 0.237 0.244 
Abbreviatures: NS = no sarcopenia; PS= probable sarcopenia; SS = severe sarcopenia; 2= result of Chi-square test; df = degrees 
of freedom; p = significance, * p< 0.05; † p< 0.01; V = Cramer’s V; T = Kendall’s Tau; aMod-Abb-Charlson-Index = Modified 
Charlson’s Comorbidity Index as a codification of total score in three comorbidity levels (Berkman et al., 1992) [33]; bModified 
falls according to its registration through the SARC-F questionnaire by Malmstrom and colleagues (2016) [21]. 
3.3. Derivation of the Regression Equation 
A logistic binary regression was estimated to predict sarcopenia vs. non-sarcopenia. The two 
groups labeled with sarcopenia (probable or severe) were merged into a single sarcopenia group due 
to the sample size needed for stable estimates. The predictors considered were age, BMI and gender 
as control variables, together with Barthel’s Index, Abbreviated Charlson’s Comorbility Index, 
medications, hospitalisation stays and falls. Having taken into account previously presented bivariate 
results, the falls measure included in the regression was the indicator with three categories since it 
showed a better predictive power than the quantitative index. Due to sample size reasons an 
automated forward selection of predictors was used. Results of this logistic regression are shown in 
Table 4. 
Table 4. Binary Logistic Regression to predict sarcopenia vs. non-sarcopenia. 
Variables B SE p Odd-Ratio 95% CI 
Age 0.101 0.03 0.001 1.16 1.04–1.17 
Barthel’s Index −0.04 0.01 0.001 0.96 0.95–0.98 
Abbreviated Charlson’s Comorbility Index 0.418 0.17 0.015 1.51 1.08–2.12 
Abbreviatures: B =  coefficient; SE = standard deviation; p = significance; CI = Confidence interval 
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Three predictors had statistically significant effects on the dependent variable. The coefficients 
and associated odds-ratio for age showed that as age increases participants are more likely to have 
sarcopenia. The negative coefficient associated with the Barthel’s Index shows that, as was more 
likely, dependent people also have sarcopenia. Finally, the Abbreviated Charlson’s Comorbidity 
Index coefficient and odds-ratio showed that people with sarcopenia tend to present more 
comorbidities. This last index is the best predictor of the likelihood of presenting sarcopenia. Overall, 
the estimated effect size for the regression was 0.25 (Cox and Snell’s R-square) and 0.34 (Nagelkerke’s 
R-square). 
3.4. Prevalence of Sarcopenia by Gender and Age 
The overall prevalence of sarcopenia according to gender, including probable sarcopenia and 
severe sarcopenia cases, is presented in Figure 2. The difference between genders did not reach the 
significance threshold (2(2) = 1.33, p = 0.512, Cramer’s V = 0.101, Kendall’s tau = −0.039). 
 
Figure 2. Percentages of no sarcopenia and severity sarcopenia levels (EWSGOP2, 2019) according to 
gender: no sarcopenia, probable sarcopenia, and severe sarcopenia. 
Table 5 shows the prevalence of sarcopenia according to age range. The participants aged over 
85 years had a higher prevalence of sarcopenia, both for probable and severe sarcopenia (2(4) = 15.06, 
p = 0.005, Cramer’s V = 0.239, Kendall’s tau = 0.276). 
Table 5. Age-stratified sarcopenia prevalence: percentages and (n). 
Sarcopenia Subtypes 65–74 Years 75–84 Years 85 Years Total 
No-sarcopenia (n = 86) 24.4% (21) 44.2% (38) 31.4% (27) 65.2% 
Probable sarcopenia (n = 18) 16.7% (3) 16.7% (3) 66.7% (12) 13.6% 
Confirmed sarcopenia (n = 0) 0% 0% 0% 0% 
Severe sarcopenia (n = 28) 3.6% (1) 35.7% (10) 60.7% (17) 21.2% 
n = 132  18.9% (25) 38.6% (51) 42.4% (56) 100% 
4. Discussion 
The present study showed that the Barthel Index, the Abbreviated Comorbidity Index and falls 
as registered in the SARC-F were significantly related with sarcopenia in institutionalised older 
adults using the EWGSOP2 algorithm. In addition, the Barthel Index, the Abbreviated Comorbidity 
Index and age of participants was shown to be able to predict sarcopenia in this population. 
Moreover, with the new algorithm, sarcopenia has been shown to be more prevalent in aged people. 
To the best of our knowledge, the EWGSOP2 algorithm in institutionalised older adults has not 
been broadly used since the most recent definition [34]. This algorithm detects probable sarcopenia 
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therefore it is highly important to identify institutionalised older adults in this category. This initial 
screening is done by finding the cases through the SARC-F, and only those identified by this tool 
have muscle strength assessed. In this regard, since all the parameters of the algorithm were analysed 
for all the participants, the descriptive data showed contradictory differences in the first two steps of 
the algorithm in relation to gender. The mean of SARC-F for men showed non-sarcopenic values, 
while women’s mean showed sarcopenic ones; however, the grip strength results were opposite. If 
using only the SARC-F for screening, this could be at the expense of missing men who would have 
been at least in the category of probable sarcopenia since they show low muscle grip strength, but are 
classified as not sarcopenic according to the SARC-F. Although the SARC-F has shown excellent 
specificity and has been widely used in the field of sarcopenia research in community-dwelling 
population [21,35–38], it has shown to have a major problem in relation to its low sensitivity. Previous 
research applying the EWGSOP definition has reported sensitivity to be 4.2% and 9.9% [35], or 14.6% 
and 33.3% [36] in men and women, respectively. The low sensitivity of SARC-F means that there is a 
high risk of a missed diagnosis of individuals who have sarcopenia, so other tools like the clinical 
and functional variables shown in this study may complement the SARC-F information and may be 
used in future research. 
Following the EWGSOP2 algorithm, once the cases of probable sarcopenia have been detected 
the confirmation must be done with muscle quantity analysis. It has been stated that low muscle mass 
potentially contributes to disability and frailty in older adults [39]. Therefore, the accurate 
measurement of muscle mass is a crucial step for classifying sarcopenic older adults, especially in 
residential facilities since residents have higher risks of adverse events. There is an ongoing debate 
about the preferred adjustment for muscle mass indices and whether the same method can be used 
for all populations [7]. This is in line with our results, where the mean ASM (kg) was below cut-off 
points for both men and women, and the mean ASM Index (kg/height2) was over cut-off points for 
both genders. The EWGSOP2 consensus presented cut-off points for both ASM Index (kg/height2) 
[40] and ASM (kg) [27] for use when calculating muscle mass. Among these parameters, in the present 
study the ASM Index (kg/height2) was chosen since it consists of an anthropometric equation which 
adjusts through body size and has been reported to have associations with clinical outcomes such as 
physical disability, frailty or cardiovascular diseases [41–43]. However, it has to be taken into account 
that the most appropriate method defining low lean mass with the highest predictive value for 
identification remains uncertain [44]. Therefore, there is a need to elucidate in future research which 
method and operational definition is ideal for identifying sarcopenic people, especially older adults 
since they are at high risk. 
In relation to the last step of the algorithm, 21% of the participants had severe sarcopenia which 
means that just over 60% of the sarcopenic people were in this category. Participants with severe 
sarcopenia not only have limited strength but also their performance is affected, which overall results 
in physical limitations [45] that can lead to adverse negative health outcomes such as care 
dependence, falls, fractures, hospitalisation and death. 
Thus, in this study participants diagnosed with the EWGSOP2 algorithm had significantly lower 
functionality and higher comorbidity, especially those with severe sarcopenia. This supports 
previous studies which have also found a relationship between the Barthel Index and sarcopenia in 
institutionalised older adults [15,16] when applying the EWGSOP definition. Comorbidity has 
previously also been shown to be associated with sarcopenia, but it has been studied in community-
dwelling people and measured by the presence of major chronic illnesses [46]. However, in the 
present study, severity of disease or comorbidity, which is an important issue in institutionalised 
older adults, has been carefully controlled by using the Abbreviated Charlson’s Comorbidity Index 
[33]. 
Furthermore, falls measured through the SARC-F were shown to be significantly related with 
sarcopenia in our population. However, in previous studies which used the EWGSOP definition with 
institutionalised older adults with sarcopenia, no significant relationship was found [15]. Overall, 
this seems to indicate, as has been previously stated, that the EWGSOP2 algorithm appears to be 
more sensitive than the EWGSOP for predicting the incidence of falls, although this has been shown 
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in community-dwelling people [47]. This is clinically important since falls in older adults are a major 
cause of injury that may result in fracture, disability, poor quality of life, and death [48]. 
The trend that can be observed among sarcopenic people of this study is that medication and 
hospitalisations have more presence with both probable and severe sarcopenic participants. Thus, it 
was observed that both men and women present polypharmacy [49,50]. However, there was no 
significant relation with sarcopenic participants nor with hospitalisations, and although it has been 
previously stated that the risk of hospitalisation is higher in sarcopenic subjects [51], this has been 
studied in relation to community-dwelling people. This highlights the need to register these variables 
by a common and objectifiable tool to avoid differences in the registry protocols of each of the 
residential facilities. 
In the regression analysis, the combination of age, Barthel Index and Abbreviated Charlson’s 
Comorbidity Index showed to be significant for predicting sarcopenia. These functional and clinical 
variables can help health care professionals in residential facilities to pay special attention to older 
people who may be heading towards suffering sarcopenia. A baseline sarcopenia assessment 
systematically carried out in residential facilities for new residents could provide important 
prognostic information regarding the patient’s future functional trajectory [52]. In this line, some 
authors have stated that the traditional medical model should move from a disease-centered 
perspective to a functioning-centered view [53]. Identifying loss of functionality and sarcopenia in 
early stages is important to prevent the progress of sarcopenia and its consequences, as well as to 
start treatment. Thus, treatment for sarcopenia is very important in residential facilities because the 
functional decline leads to a loss of independence in older adults and is associated with a higher 
demand for services in residential centers [54]. Therefore, the prevention of sarcopenia has become 
one of the major goals of public health professionals and clinicians [53], and easily applied tools for 
identifying it are of great importance. 
As for the prevalence of sarcopenia, the application of the EWGSOP2 algorithm has shown that 
nearly 35% of the sample had some level of sarcopenia, which is within the wide range observed in 
previous studies of prevalence implemented in residential facilities up to the moment (17.7%–73.3%) 
[54]. However, most of the studies carried out in this population have followed the EWGSOP 
algorithm [3,15]. Due to the novelty of the EWGSOP2 consensus, only one previous study has applied 
it in residential facilities [34] and showed a prevalence of 60%. Considering that their inclusion criteria 
was people aged 70 or more (higher age than our criteria) and that consequently their participants 
had a mean age of 85 years which is slightly higher than in the present study, and that sarcopenia is 
related to age [15], this can partially explain it. Future research with the EWGSOP2 algorithm in 
institutionalised older people could help ascertain the trends. 
The EWGSOP2 definition classified the sarcopenic patients depending on the physical 
performance. The different categories showed that people with sarcopenia were mostly the older 
ones, and they were mainly diagnosed with severe sarcopenia. This is in line with other studies 
[15,55] which highlight the fact that in residential facilities people tend to have more dependency and 
disabilities [56]. 
Studies that have used the EWGSOP definition have found differences between gender but with 
contradictory conclusions. Some studies have shown women having a higher prevalence of 
sarcopenia than men (81.4% of sarcopenic patients), and in other studies—like the one conducted by 
Landi et al.—a higher ratio of sarcopenia corresponded to men [24]. When using the EWGSOP2 
algorithm, no differences were found. 
Taking into account that, currently, most health care professionals lack guidance or training to 
recognise and manage the decline in physical capacities in older age [45], our study offers promising 
results in relation to the assessment of sarcopenia with simple and available tools, such as the Barthel 
Index and Abbreviated Charlson’s Comorbidity Index. 
Limitations and Strengths 
The main limitation of our study, common to other studies in residential facilities, is related to 
the inclusion criteria, which can exclude people with a greater probability of having sarcopenia and 
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underestimate its prevalence. Another limitation is that the majority of the sample were women, and 
although this is characteristic related to aged population in Spain, greater equality between the sexes 
and their ages would be important in future research. This study offers the novelty of applying all of 
the steps of the updated definition of sarcopenia, plus the definition was applied on an 
institutionalised population, which has not been so broadly studied. Moreover, our results offer 
health professionals a new use to well-known tools that can support the identification of sarcopenia. 
5. Conclusions 
A functional tool, such as the Barthel Index widely used in residential facilities, and a clinical 
and objective index, such as the Abbreviated Charlson’s Comorbidity Index, can be considered 
predictors that guide healthcare professionals. This may support early sarcopenia identification and 
therapeutic approaches. Future research, with greater sample sizes and equality between gender and 
ages, may elucidate which of the different options of the EWGSOP2 algorithm may be more sensible 
to detect sarcopenic people, both in institutionalised and community-dwelling older adults. 
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